Evaluation of clinical benefit from treatment with mepolizumab for eosinophilic granulomatosis with polyangiitis

This post hoc assessment of a recent clinical trial of mepolizumab in patients with EGPA demonstrates that patients not achieving protocol-defined remission still met important clinical endpoints of remission, glucocorticoid dose reduction and no relapses. (Source: Journal of Allergy and Clinical Immunology)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://bit.ly/2Bx0OFp